Original Research
Monday, October 14, 2024
01:00 PM–02:30 PM
Abstract
Introduction: Candida auris (C. auris) presents a therapeutic challenge due to undefined susceptibility breakpoints and frequent misidentification by biochemical tests, leading to suboptimal therapy
Research Question or Hypothesis: What are the clinical outcomes of management C. auris infections?
Study Design: A retrospective observational cohort study.
Methods: The study was conducted between January 2019 and June 2022, including confirmed cases of C. auris infection. The primary endpoint was to assess the clinical outcomes of C. auris management. Secondary endpoints included mycologic cure, 30-day and 90-day infection recurrence, and 30-day all-cause mortality.
Results: A total of 56 patients were evaluated, with a mean age of 65.05±16.86 years. Candidemia accounted for 62.7% of cases. Clinical cure was achieved in 57% of patients, while mycologic cure was achieved in 84.4%. Recurrence of C. auris infection occurred in 28.6% of patients at 30 days and 12.7% at 90 days. The 30-day mortality rate was 28.6%. Multivariate logistic regression identified mycologic cure [OR 6.96; 95% CI (1.21-39.92)], length of critical care unit stay [OR 0.132; 95% CI (0.019-0.907)], and baseline C-reactive protein levels [OR 0.990; 95% CI (0.982-0.998)] as the independent predictors of clinical cure.
Conclusion: The clinical cure of invasive C. auris infections was predicted by mycologic cure, shorter critical care stay, and low C-reactive protein levels. Further multi-center studies are needed to validate our findings.
Presenting Author
Wasim Elnekidy PharmD, BCPS, BCACPCleveland Clinic Abu Dhabi
Authors
Emna Abidi PhD
Cleveland Clinic Abu Dhabi
Calude Afif MD
Cleveland Clinic Abu Dhabi
Sara Al Jabi PharmD
Cleveland Clinic Abu Dhabi
Rania El Lababidi PharmD, BCPS (AQ-ID), AAHIVP
Cleveland Clinic Abu Dhabi